DIRECT: A Clinical Study for Stage III Pancreatic Cancer
This year, an estimated 57,600 new cases of pancreatic cancer will be diagnosed in the United States alone.1 It is our hope that DIRECT will provide a potential treatment option for these people during their battle with cancer.
Dealing with pancreatic cancer can be overwhelming, but support can be found all around you. Talk with your family, reach out to support organizations such as PanCAN and ACS (American Cancer Society), and lean on your healthcare team to guide you through all of your options.
What is DIRECT?
DIRECT is a clinical study for stage III pancreatic cancer sponsored by AngioDynamics, Inc. This comprehensive clinical study will evaluate the effects of Irreversible Electroporation (IRE) ablation technology on the treatment of stage III pancreatic cancer.
DIRECT is composed of a real-world, controlled Registry and an additional Randomized Control Trial (RCT). This innovative study is designed to provide the most complete form of evidence available to patients, clinicians, payors and regulators.
DIRECT is led by Co-Principal Investigators – Govindarajan Narayanan, MD, Chief of Interventional Oncology at Miami Cancer Institute and Robert C.G. Martin, MD, PhD, Surgical Oncology at the University of Louisville. Together, with their extensive medical experience and passion towards clinical studies and research, we hope to drive DIRECT forward.
How to Learn More
If you would like to learn more about DIRECT, including information on active hospital sites that are enrolling and patient qualifying information, please call our study support line at +1 (800) 584-7608.
1 Cancer Facts & Figures 2020. American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdfAccessed February 26, 2020.
AngioDynamics, the AngioDynamics logo and NanoKnife are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. © 2020 AngioDynamics, Inc. GL/ON/WP/105 Rev 01 02/20